CityUHK researchers unveil the mystery of “Asian Flush” mechanism, pioneering new directions in precision treatment for heart attacks
HONG KONG, March 12, 2026 /PRNewswire/ -- Approximately 40% of the East…
Zealthy Hydroquinone 2026: Compounded Prescription Details, Online Dermatology Consultation Pricing, and What Consumers Should Verify Before Starting Treatment
New York, NY, Feb. 27, 2026 (GLOBE NEWSWIRE) -- This article contains…
Zealthy ED Platform in 2026 (Including Hardies Sublingual Formulations): Telehealth ED Treatment Options, Compounded Medication Pricing, and What Consumers Should Verify Before Starting
New York, NY, Feb. 27, 2026 (GLOBE NEWSWIRE) -- This article contains…
Discovery linking gut bacteria to cancer treatment wins the Bial Award in Biomedicine and earns 350,000 prize
A study published in Science reveals that a healthy gut microbiota can…
U.S. Food and Drug Administration (FDA) Accepts Tevas New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the…
MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
Month over Month Growth of 336% and 54% Reduction in Customer Acquisition…
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
February 11, 2026 06:00 ET | Source: Upstream Bio – Verekitug provided…
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet in the treatment of canine mast cell tumors
PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS…
Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer
DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast…
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader…
